Abstracts tagged "drug safety and registries"

Abstract Number: 2760 • 2013 ACR/ARHP Annual Meeting
Incidence and Severity Of Myocardial Infarction In Subjects Receiving Anti Tumour Necrosis Factor Drugs For Rheumatoid Arthritis: Results From Linking the British Society For Rheumatology Biologics Register For Rheumatoid Arthritis and Myocardial Ischaemia National Audit Project
Audrey SL Low¹, Kimme L. Hyrich², Mark Lunt³, Louise K. Mercer³, Christopher Gale^4,5, Kath Watson⁶, British Society for Rheumatology Biologics Registers (BSRBR) Control Centre Consortium¹, William G. Dixon⁷, Deborah P. Symmons^3,8 and On behalf of the BSRBR⁹, ¹Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, ²Arthritis Research UK Epidemiology Unit, Manchester Academic Health Sciences Centre, Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, ³Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester, United Kingdom, ⁴Division of Epidemiology, Centre for Epidemiology and Biostatistics, University of Leeds, Leeds, United Kingdom, ⁵Department of Cardiology,York Teaching Hospital NHS Foundation Trust, York, United Kingdom, ⁶Arthritis Research UK Epidemiology Unit, Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, ⁷The University of Manchester, Manchester, United Kingdom, ⁸Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom, ⁹British Society for Rheumatology, London, United Kingdom
Background/Purpose: Subjects with rheumatoid arthritis (RA) are at increased risk of myocardial infarction (MI) compared to subjects without RA, with the increased risk potentially driven…
Abstract Number: 377 • 2013 ACR/ARHP Annual Meeting
Risk Factors For Stroke In Patients With Rheumatoid Arthritis
Anja Strangfeld¹, Yvette Meißner², Adrian Richter³, Matthias Schneider⁴, Hans Peter Tony⁵, Kerstin Gerhold⁶, Angela Zink⁷ and Joachim Listing³, ¹Programme Area Epidemiology, German Rheumatism Research Center, a Leipniz Institute, Berlin, Germany, ²Programme Area Epidemiology, German Rheumatism Research Center Berlin, Berlin, Germany, ³German Rheumatism Research Center, Berlin, Germany, ⁴Department of Endocrinology, Diabetes and Rheumatology, University of Duesseldorf, Duesseldorf, Germany, ⁵Rheumatology/Immunology, University of Würzburg, Würzburg, Germany, ⁶Programme Area of Epidemiology, German Rheumatism Research Center, a Leipniz Institute, Berlin, Germany, ⁷German Rheumatism Research Centre and Charité University Medicine, Berlin, Germany
Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased risk of stroke. This event is associated with considerable sequelae and might result in death or…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].